98%
921
2 minutes
20
Lymphoma is a rare malignancy of the breast, comprising approximately 0.04 to 0.5% of breast malignancies. Because the clinical findings of breast lymphoma are nonspecific and similar to those of breast carcinoma, it is important to distinguish breast lymphoma from other breast disease on the basis of radiologic findings. Elastography is an interesting imaging tool that reflects the tissue stiffness, increasingly being used in the evaluation of breast tumours. However, only a limited number of studies have focused on the elastographic findings of breast lymphoma. In this report, we review the radiologic characteristics of primary breast lymphoma including elastographic feature. A 57-year-old woman presented with a painless palpable mass of the left breast. Ultrasonography revealed an irregular-shaped complex cystic and solid mass with increased vascularity in upper outer breast. On shear wave elastography, the mass was relatively stiff with maximum elasticity value (E) of 100.5 kilopascal (kPa). The mass was confirmed as diffuse large B-cell lymphoma by US-guided core needle biopsy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296546 | PMC |
http://dx.doi.org/10.7860/JCDR/2016/22612.9062 | DOI Listing |
Sage Open Pediatr
September 2025
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Objective: To report the incidence and survival patterns for children, adolescents, and young adults (CAYA) cancer survivors over the past 20 years.
Methods: CAYA (under 25 years old) cancer survivors from 17 Surveillance, Epidemiology, and End Results (SEER) registries from 2000 to 2020 were analyzed. A joinpoint regression model was used to analyze the incidence and 5-year survival rate.
J Surg Case Rep
September 2025
Department of Pathology, Sengkang General Hospital, 110 Sengkang East Way, 544886, Singapore.
Lymphoma involving the breast is an uncommon clinical entity, comprising ˂0.5% of all breast malignancies. Due to its rarity, there is no standardized treatment approach.
View Article and Find Full Text PDFMol Cancer Ther
September 2025
David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery and the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid cell leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance.
View Article and Find Full Text PDFInt J Cancer
September 2025
Department of Public Health and AI, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.
Population aging is an increasing challenge for cancer control in rapidly aging societies, yet remains inadequately quantified. We aim to project and illustrate the cancer burden attributable to aging in Korea by utilizing age-period-cohort (APC) models and population attributable fraction (PAF) concepts. From population-based cancer data, incidence and mortality of cancers primarily affected by aging (stomach, colorectal, liver, gallbladder, pancreatic, lung, non-Hodgkin lymphoma, esophagus, prostate, ovarian, male bladder cancers, and female leukemia) and breast cancer were extracted.
View Article and Find Full Text PDFInvest New Drugs
September 2025
Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Universidad Autónoma de Madrid, Módulo 13, 28049, Madrid, Spain.
The oncogenic transcription factor MYC drives proliferation, metabolism, and therapy resistance in the majority of human cancers, yet its large, nuclear protein-protein interface has long frustrated direct drug discovery. A pivotal breakthrough was the identification of Tribbles pseudokinase 3 (TRIB3) as a high-affinity scaffold that binds the helix-loop-helix/leucine zipper region of MYC, blocks the E3-ubiquitin-ligase, UBE3B, from tagging critical lysines, and thereby prolongs MYC protein half-life while enhancing MYC-MAX transcriptional output. This review integrates structural, biochemical, and in vivo data to show how genetic deletion or pharmacological eviction of TRIB3 collapses MYC levels, silences its gene program, and suppresses tumor growth in B-cell lymphomas and selected solid tumors.
View Article and Find Full Text PDF